Altimmune, Inc.
For the period ended Dec 31, 2025. Filed Mar 6, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Power of Attorney
BY THESE PRESENTS, each person whose signature appears below constitutes and appoints Jerome Durso and Gregory Weaver his true and lawful attorney-in-fact and agents, with full power of substitution and resubstitution for him and in his name, place and stead, in any and all capacities to sign any and all amendments to this annual report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the U.S. Securities and Exchange Commission, hereby ratifying and confirming all that said attorney-in-fact or his substitute, each acting alone, may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| | | |||
| Signature | | Title | | Date |
|---|---|---|---|---|
| | | |||
| /s/ Jerome DursoJerome Durso | | Chairman of the Board of Directors, President and Chief Executive Officer (Principal Executive Officer) | | March 6, 2026 |
| | | |||
| /s/ Gregory WeaverGregory Weaver | | Chief Financial Officer, (Principal Financial Officer and Principal Accounting Officer) | | March 6, 2026 |
| | | |||
| /s/ John GillJohn Gill | | Director | | March 6, 2026 |
| | | |||
| /s/ Philip HodgesPhilip Hodges | | Director | | March 6, 2026 |
| | | |||
| /s/ Diane Jorkasky, M.D.Diane Jorkasky, M.D. | | Director | | March 6, 2026 |
| | | |||
| /s/ Teri LawverTeri Lawver | | Director | | March 6, 2026 |
| | | |||
| /s/ Wayne PisanoWayne Pisano | | Director | | March 6, 2026 |
| | | |||
| /s/ Mitchel Sayare, Ph.D.Mitchel Sayare, Ph. D. | | Director | | March 6, 2026 |
| | | |||
| /s/ Klaus O. Schafer, M.D.Klaus O. Schafer, M.D. | | Director | | March 6, 2026 |
| | | |||
| /s/ Catherine Sohn, Pharm D.Catherine Sohn, Pharm D. | | Director | | March 6, 2026 |
| | | | | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.